TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03598478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TC-MPT
Description: Participants will receive two levels of training within each 90-minute session over a 12-week period: (1) TC training and (2) MPT. The TC training protocol consists of five basic TC movements. After receiving TC training, the participants in this group will take a 5-minute break and then receive MPT. During MPT, the participants will contract their major postural muscles bilaterally as fast as possible against a resistance equivalent to 70% of one repetition maximum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TC
Description: Children in the TC group will skip the MPT session and practice TC movements repeatedly for 90 minutes. The exercise progression pattern in the TC-alone group will be the same as that in the TC-MPT group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MPT
Description: Those children in the MPT group will perform strengthening exercises repeatedly for 90 minutes, with a short 5-minute break between the three sets of exercises if necessary. The exercise progression pattern in the MPT-alone group will be the same as that in the TC-MPT group.
Study: NCT04283552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic PET/CT Imaging
Description: -Will take approximately 60 minutes
Study: NCT04260906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus nerve stimulator
Description: Vagus nerve stimulation is carried out with a TENS device, which has specially designed surface electrodes in the shape of earphones, the size of which can be selected according to ear size. Electrodes were placed to correspond with the inner and rear surfaces of the tragus and the concha for both ears (Figure 1). The application is carried out, for 30 minutes, using a biphasic, asymmetrical waveform with a pulse duration that is less than 500 microseconds and a frequency of 10 Hertz.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: The exercise group was assigned a program, which consisted of strengthening, stretching, isometric and posture exercises, targeting the body and upper and lower extremities. That program was home-based and the program was requested to be completed. Patients were asked to attend weekly face to face sessions with a total of 4 of these sessions in the study duration.
Study: NCT01921491

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing Application
Description: Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dressing Application
Description: Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading.

Intervention type: DEVICE
Group type: OTHER
Intervention: Offloading
Description: Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading.
Study: NCT01370486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: melatonin cp 2 mg 1x/d for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo cp 1x/d for 1 month
Study: NCT04732988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study: NCT00905788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prevention of embryo expulsion
Description: The prevention of embryo expulsion will be carried out after embryo transfer
Study: NCT00623792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative lifestyle Intervention
Description: 6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery
Study: NCT03093467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASCENSO
Description: Internet-based program: an adjunct support and monitoring system for the treatment of depression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.
Description: Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.
Description: Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
Study: NCT00506298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bezafibrate + diflunisal
Description: bezafibrate + diflunisal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bezafibrate + placebo
Description: bezafibrate + placebo
Study: NCT00478478

Intervention type: PROCEDURE
Intervention: Mechanical Thrombectomy
Description: Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
Study: NCT02244411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual diet & physical activity counselor and website through Healthways at Hopkins
Description: Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self directed weight loss
Description: Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasting blood draw, measurement of height, weight and waist circumference, and blood pressure
Description: During three time periods, at baseline and at 12 and 24 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fasting blood draw, measurement of height, weight and waist circumference, and blood pressure
Description: During three time periods, at baseline and at 12 and 24 months.
Study: NCT02304952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency microtenotomy
Description: For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise
Description: Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocare Topaz MicroDebrider
Study: NCT01428297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPR277 ointment (controlled application)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Vehicle)
Study: NCT04555278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). The intensity of rTMS will be set at 95 % of the first dorsal interosseous (FDI) resting motor threshold (RMT).~Active rTMS will consist of 40 trains of 5 seconds each at 10 Hz (25-s intertrain interval) applied over M1 (on FDI cortical representation), for a total of 2000 stimulations lasting 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). The intensity of rTMS will be set at 95 % of the first dorsal interosseous (FDI) resting motor threshold (RMT).~Active rTMS will consist of 40 trains of 5 seconds each at 10 Hz (25-s intertrain interval) applied over M1 (on FDI cortical representation), for a total of 2000 stimulations lasting 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: A sham coil will be use (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS (30 min).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: A sham coil will be use (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS (30 min).
Study: NCT02794571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.
Study: NCT04555278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Exercises
Description: The rehabilitation program will consist of a 30-minute session of motor control exercises following the rTMS (Active or Sham) intervention. This approach aims to improve spine health through the optimization of spine loading. The first session will be preceded by an individualized evaluation of the participant's abilities and deficiencies to tailor the training program to each participant.
Study: NCT01428297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPR277 ointment
Study: NCT04555278

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Motor Control Exercises
Description: The rehabilitation program will consist of a 30-minute session of motor control exercises following the rTMS (Active or Sham) intervention. This approach aims to improve spine health through the optimization of spine loading. The first session will be preceded by an individualized evaluation of the participant's abilities and deficiencies to tailor the training program to each participant.
Study: NCT01368926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: single oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral doses
Study: NCT01358552

Intervention type: OTHER
Intervention: Néevo®/ NéevoDHA®
Description: Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
Study: NCT01739725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent insertion
Description: The patient will receive the helical stent
Study: NCT02382549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRAF inhibitor
Description: BRAF inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK inhibitor
Description: MEK Inhibitor
Study: NCT03651726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THX-110 (dronabinol plus PEA)
Description: 2.5 mg dronabinol capsules and 400 mg PEA tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
Study: NCT02459041

Intervention type: OTHER
Intervention: Elastography, contrast enhancement
Description: Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors.

Intervention type: OTHER
Intervention: Elastography, contrast enhancement
Description: Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors.

Intervention type: OTHER
Intervention: Elastography, contrast enhancement
Description: Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors.

Intervention type: OTHER
Intervention: Elastography, contrast enhancement
Description: Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors.
Study: NCT02355756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxadilan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00782028

Intervention type: OTHER
Group type: OTHER
Intervention: Centering parenting/Group well child care
Description: Intervention families will receive well child care in a group format for the first 12 month of the child's life.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard Care
Study: NCT02340494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Enhanced Education Tool
Description: The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
Study: NCT02083419

Intervention type: DEVICE
Intervention: LVAD CRT
Description: The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
Study: NCT01428297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPR277
Study: NCT03811626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral rehabilitation
Description: Combination of clinical examination and neuropsychological and psychological tests
Study: NCT01965184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Anger and Aggression
Study: NCT01428297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Vehicle)
Study: NCT04062760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard diuretic therapy
Description: The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early sequential nephron blockade
Description: After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~1. oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~2. metolazone at a dose based on serum creatinine value~3. acetazolamide at a dose based on serum creatinine value~4. spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value
Study: NCT02975310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic polypectomy in clinic (EPIC)
Description: The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Sinus Surgery (ESS)
Description: The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.